Investor Presentaiton

Investor presentation ADA 2019 Slide 6 GLP-1s have positive effects beyond glycaemic control and treatment guidelines have been updated to particularly reflect the CV risk benefits The multifactorial effects of GLP-1s Heart ADA/EASD diabetes treatment guidelines for second- line treatment with established ASCVC or CKD1 First-line therapy is metformin and lifestyle management. If HbA1c above target, proceed as below Established ASCVD or CKD NO Without established ASCVD or Pancreas Beta-cell function² Beta-cell apoptosis² Insulin biosynthesis² Glucose-dependent insulin secretion² Glucose-dependent glucagon secretion² Liver Endogenous glucose production 11 Hepatic insulin sensitivity 11 De novo lipogenesis 11 Lipotoxicity11 Steatosis 12 CV risk³ Fatty acid metabolism4 Cardiac function4 Systolic blood pressure4 Inflammation5 Atherosclerotic plaque progression 5 Brain Body weight6 Food intake ↑ Satiety 8,9 All references and notes on slide 37 YES ASCVD predominates GLP-1 with proven CVD benefit* EITHER/ OR CKD SGLT-2 with proven CVD benefit*, if eGFR adequate HF OR CKD predominant Incretin system Replacement of deficient GLP-1 response 10 If HbA1c above target If further intensification is required or patient is now unable to tolerate GLP-1 and/or SGLT-2, choose agents demonstrating CV safety... SIMPLIFIED ILLUSTRATION

View entire presentation